Table 3. Clinical characteristics according to post-EGFR-TKI TPS for PD-L1 and CD8+ TIL (n = 69).
| TPS for PD-L1/CD8+ TIL score | PD-L1 TPS< 1% or high CD8+TIL (n = 52) | PD-L1TPS≥ 1% and low CD8+ TIL (n = 17) | P value |
|---|---|---|---|
| M/F | 14/38 | 5/12 | 1.0 |
| Smoking | 0.410 | ||
| Current or ex-smoker | 11 (21.2%) | 4 (23.5%) | |
| Never smoker | 41 (78.8%) | 13 (76.5%) | |
| Treatment before rebiopsy | 0.472 | ||
| EGFR TKI | 44 (86.4%) | 13 (76.5%) | |
| Cytotoxic chemo | 8 (15.4%) | 4 (23.5%) | |
| Age (mean, Years) | 62.3 | 61.5 | 0.771 |
| EGFR mutation at diagnosis | 0.163 | ||
| Exon19 | 36 (69.2%) | 13 (76.5%) | |
| Exon 21 and others | 16 (30.8%) | 4 (23.5%) | |
| PFS (Mo) of EGFR-TKI | 14.2 (12.7–15.7) | 9.9 (3.3–16.5) | 0.060 |
| EGFR Exon 20 T790M mutation after EGFR-TKI | |||
| Exon20T790M | 18 (34.6%) | 4 (23.5%) | 0.403 |
| No exon20 T790M | 34 (65.4%) | 13 (76.5%) | |
| Stage | 0.384 | ||
| IIIB/IVA | 16 (30.7%) | 8 (47.1%) | |
| IVB | 36 (69.3%) | 9 (52.9%) | |
| Presence of brain metastasis | 18 (34.6%) | 6 (35.3%) | 0.959 |